Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 26/5/2017
SIETES contiene 91804 citas

 
 
 1 a 20 de 1391 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
2. Cita con resumen
Anónimo. Drugs for hypertension. The Medical Letter on Drug and Therapeutics Bulletin 2017;59:41-8. [Ref.ID 101527]
3. Cita con resumen
Nardone B, Majewski S, Kim AS, Kiguradze T, Martínez-Escala EM, Friedland R, Amin A, Laumann AE, Edwards BJ, Rademaker AW, Martini MC, West DP. Melanoma and non-melanoma skin cancer associated with angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers and thiazides: a matched cohort study. Drug Saf 2017;40:249-55. [Ref.ID 101451]
4. Cita con resumen
Chobanian AV. Hypertension in 2017- What is the right target?. JAMA 2017;317:579-80. [Ref.ID 101415]
5. Cita con resumen
Anónimo. Spironolactone - potion or poison?. Drug Ther Bull 2017;55:13. [Ref.ID 101402]
6.Tiene citas relacionadas Cita con resumen
Puttnam R, Davis BR, Pressel SL, Whelton PK, Cushman WC, Louis GT, Margolis KL, Oparil S, Williamson J, Ghosh A, Einhorn PT, Barzilay JI, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group.. Association of 3 different antihypertensive medications with hip and pelvic fracture risk in older adults: secondary analysis of a randomized clinical trial. JAMA Intern Med 2017;177:67-76. [Ref.ID 101344]
7.Enlace a cita original Cita con resumen
Roustit M, Genty C, Lepelley M, Blaise S, Fromy B, Cracowski J-L, Bosson J-L. Amiloride treatment and increased risk of pressure ulcers in hospitalized patients. Br J Clin Pharmacol 2016;82:1685-7. [Ref.ID 101027]
9. Cita con resumen
Munson JC, Bynum JPW, Bell J-E, Cantu R, McDonough C, Wang Q, Tosteson TD, Tosteson ANA. Patterns of prescription drug use before and after fragility fracture. JAMA Intern Med 2016:22 de agosto. [Ref.ID 100584]
10. Cita con resumen
Finch A, Kubler P. The management of gout. Australian Prescriber 2016;39:1 de agosto. [Ref.ID 100572]
11. Cita con resumen
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957-67. [Ref.ID 100151]
12. Cita con resumen
Griebeler ML, Kearns AE, Ryu E, Thapa P, Hathcock MA, Melton LJ, Wermers RA. Thiazide-associated hypercalcemia: incidence and association with primary hyperparathyroidism over two decades. J Clin Endocrinol Metab 2016;101:1166-73. [Ref.ID 100079]
13.Enlace a cita original Cita con resumen
Anónimo. Riesgos de los fármacos anticolinérgicos en personas de edad avanzada. Butlletí Groc 2015;28:1-4. [Ref.ID 99838]
14. Cita con resumen
Fathallah N, Slim R, Larif S, Hmouda H, Ben Salem C. Drug-induced hyperglycaemia and diabetes. Drug Saf 2015;38:1153-68. [Ref.ID 99783]
15.Enlace a cita original Cita con resumen
Park H, Satoh H, Miki A, Urushihara H, Sawada Y. Medications associated with falls in older people: systematic review of publications from a recent 5-year period. Eur J Clin Pharmacol 2015;71:1429-40. [Ref.ID 99782]
16.Tiene citas relacionadas
Sternlicht H, Bakris GL. Spironolactone for resistant hypertension—hard to resist?. Lancet 2015;386:2032-4. [Ref.ID 99769]
17. Cita con resumen
Jorgensen ME, Hlatky MA, Kober L, Sanders RD, Torp-Pedersen C, Gislason GH, Jensen PF, Andersson C. ß-blocker-associated risks in patients with uncomplicated hypertension undergoing noncardiac surgery. JAMA Intern Med 2015;175:1923-31. [Ref.ID 99749]
18. Cita con resumen
Anónimo. Hypertension artérielle essentielle chez un adulte: premiers traitements. Prescrire 2015;35:683-6. [Ref.ID 99722]
19. Cita con resumen
Anónimo. Hyponatrémies d'origine médicamenteuse. Prescrire 2015;35:666-71. [Ref.ID 99717]
20.Tiene citas relacionadas Cita con resumen
Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ, for The British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059-68. [Ref.ID 99524]
Seleccionar todas
 
 1 a 20 de 1391 siguiente >>